Cargando…
A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model [Corrigendum]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094641/ https://www.ncbi.nlm.nih.gov/pubmed/35572619 http://dx.doi.org/10.2147/OTT.S372818 |
Ejemplares similares
-
A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model
por: Li, Xin-Long, et al.
Publicado: (2020) -
Corrigendum to: Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment
Publicado: (2021) -
CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017) -
Corrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy”
por: Guo, Qiujun, et al.
Publicado: (2018) -
Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
por: D'Angelo, S. P., et al.
Publicado: (2015)